Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Non-Current Assets (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Other Non-Current Assets for 6 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 23017.24% year-over-year to $6.7 million, compared with a TTM value of $6.7 million through Dec 2025, up 23017.24%, and an annual FY2025 reading of $6.7 million, up 23017.24% over the prior year.
  • Other Non-Current Assets was $6.7 million for Q4 2025 at Cytek Biosciences, up from $4.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $6.7 million in Q4 2025 and bottomed at $29000.0 in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $2.9 million, with a median of $2.9 million recorded in 2023.
  • The sharpest move saw Other Non-Current Assets crashed 99.14% in 2024, then soared 23017.24% in 2025.
  • Year by year, Other Non-Current Assets stood at $1.7 million in 2021, then soared by 74.11% to $2.9 million in 2022, then rose by 16.76% to $3.4 million in 2023, then plummeted by 99.14% to $29000.0 in 2024, then skyrocketed by 23017.24% to $6.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CTKB at $6.7 million in Q4 2025, $4.5 million in Q3 2025, and $29000.0 in Q4 2024.